Characterization of Bleeding Disorders in EDS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-01

Study Completion Date

2024-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ehlers-Danlos Syndrome (EDS) is a disease that weakens the connective tissues (i.e. tendons and ligaments) in the human body. EDS can make the joints loose and alter skin and wound healing. It can also weaken blood vessels and organs. Many EDS patients are referred for investigation of bleeding symptoms. Although most patients will have mild symptoms such as bruising, many will experience significant bleeding that can be life-threatening. The physiological reason behind this has not been identified and therefore, treating this is challenging. In addition, patients with EDS frequently require major surgery due to complications from their connective tissue disease. These surgery carries a significant risk of catastrophic bleeding which is further magnified in this group of patients. The specific reason of clinical bleeding in patients with EDS is likely multifactorial, including skin and blood vessel fragility leading to increased bruising and poor wound healing, coagulopathies related to factor deficiency, acquired vonWillebrand disease (VWD), and notable platelet dysfunction.

Despite compelling preliminary evidence, there is limited data on the diagnosis and management of platelet dysfunction in EDS patients. Therefore, in this study we will characterize hemostasis, the medical term which refers to the process of stopping blood flow, across the three most common subtypes of EDS.we will also determine the burden of illness of pathologic bleeding in patients with Ehlers-Danlos Syndrome (EDS) using validated patient reported tools.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rare Inherited Bleedig Disorders in Children at Sohag University Hospital

NCT05381922

Rare Inherited Bleeding Disorders in Children at Sohag University Hospital

UNKNOWN

Bleeding of Unknown Cause: a Swiss Case-control Study

NCT05713734

Bleeding Disorder

RECRUITING

Changes in Bleeding and Clotting During the Menstrual Cycle

NCT00480545

Von Willebrand's Disorder Healthy

WITHDRAWN

Association Between Perioperative Platelet Function and Major Adverse Perioperative Events

NCT00901030

Surgery

COMPLETED

Bleeding Events Before vs After Lowering Departmental Platelet Transfusion Trigger

NCT06187831

Bleeding Central Line Complication Thrombocytopenia +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ehlers-Danlos Syndrome EDS Classical Ehlers-Danlos Syndrome Classical EDS (cEDS) Hypermobile Ehlers-Danlos Syndrome Hypermobile EDS (hEDS) Vascular Ehlers-Danlos Syndrome Vascular EDS (vEDS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

* Any adult (≥ 18 years) patient with a known diagnosis of Ehlers Danlos Syndrome (Subtypes Classical, Hypermobile, or Vascular) as per the 2017 International Classification of Ehlers Danlos Syndrome.